In order to study the efficacy of new combinatorial treatments involving anti-CTLA-4 and anti-EGFR drugs, we decided to test ipilimumab on a panel of tumor cells with other anti-EGFR specific compounds, such as aptamers [31]. This evidence concerns the gene EGFR and neoplasm.